[Congressional Record Volume 172, Number 71 (Wednesday, April 22, 2026)]
[Senate]
[Page S1981]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 5028. Mr. WELCH submitted an amendment intended to be proposed by 
him to the concurrent resolution S. Con. Res. 33, setting forth the 
congressional budget for the United States Government for fiscal year 
2026 and setting forth the appropriate budgetary levels for fiscal 
years 2027 through 2035; which was ordered to lie on the table; as 
follows:

         At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO 
                   PROHIBITING DRUGS WITH ORPHAN DRUG DESIGNATIONS 
                   FROM BEING EXEMPT FROM MEDICARE DRUG PRICE 
                   NEGOTIATION.

         The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     prohibiting drugs with orphan drug designations from being 
     exempt from Medicare drug price negotiation by the amounts 
     provided in such legislation for those purposes, provided 
     that such legislation would not increase the deficit over the 
     period of the total of fiscal years 2026 through 2035.
                                 ______